BBH - VanEck Vectors Biotech ETF

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
123.70
+0.92 (+0.75%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close122.78
Open122.79
Bid123.08 x 1000
Ask123.94 x 1200
Day's Range122.79 - 124.42
52 Week Range103.25 - 136.84
Volume9,139
Avg. Volume12,300
Net Assets344.58M
NAV123.88
PE Ratio (TTM)N/A
Yield0.45%
YTD Return11.27%
Beta (3Y Monthly)1.32
Expense Ratio (net)0.35%
Inception Date2011-12-20
Trade prices are not sourced from all markets
  • Top-Performing Biotech ETFs YTD
    Zacks

    Top-Performing Biotech ETFs YTD

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.

  • Amgen to Buy Celgene's Otezla: 5 ETF Drugs
    Zacks

    Amgen to Buy Celgene's Otezla: 5 ETF Drugs

    Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

  • Biotech ETFs in Focus on Impressive Q2 Earnings Results
    Zacks

    Biotech ETFs in Focus on Impressive Q2 Earnings Results

    Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.

  • AbbVie to Buy Allergan: Prescribed ETFs
    Zacks

    AbbVie to Buy Allergan: Prescribed ETFs

    AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

  • 3 Large-Cap Biotech Stocks to Buy for Massive Gains
    InvestorPlace

    3 Large-Cap Biotech Stocks to Buy for Massive Gains

    Do you want to find the next Apple (NASDAQ:AAPL) or Amazon (NASDAQ:AMZN)? My advice is that you should set your sights lower, not higher and put some cash to work in three down, but not out heavyweight biotech stocks for the next big thing in investing. Let me explain.It has been a good week so far for the broader markets. The Nasdaq Composite, S&P 500 and Dow Jones Industrial Average have broken out of short bases barely discernible on the weekly chart and back within spitting distance of their respective all-time-highs following May's abrupt correction. It has been a nice period for biotech stocks as well.The Vaneck Vectors Biotech ETF (NYSEARCA:BBH) is up nearly 3.50% through Tuesday's close compared to gains of roughly 1% to 2% for the broader averages. But as any investor with a passing interest in the markets knows, the outperformance in biotech stocks has been anything but a recurring theme these past couple years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer The good news is markets are cyclical. Even legendary investments such as AMZN or the sacrosanct AAPL stock have been known to correct for periods lasting not weeks, but months and even years. With that in mind, it's time to consider adding these three large-cap biotech stocks into your portfolio. Amgen (AMGN) Click to EnlargeAmgen (NASDAQ:AMGN) is a biotech heavyweight that also happens to be the sector's largest capitalization outfit with a valuation of about $110 billion.Following a recent sales and earnings beat, this reasonably-priced biotech giant, which pays investors nearly 3.5% in quarterly dividends, has now put together a bottom on the monthly price chart.Specifically, AMGN stock has formed a confirmed pivot low, which reaffirms its longstanding uptrend after a correction of several months. And with plenty of lateral, angular and Fibonacci price supports, as well as an oversold crossover signal to confirm the bottom, this biotech stock is a buy today.The TradeBuy AMGN stock at current prices. Set a stop-loss beneath support below $160, but expect shares to hit new highs in 2019's second half. Gilead Sciences (GILD) Click to EnlargeIt has been a rough few years for Gilead Sciences (NASDAQ:GILD), one the sector's largest names, but things are looking up for GILD stock lately.A recent earnings report that reiterated the company's full-year guidance and offered a modest year-over-year uptick in sales and profits looks promising for Gilead shares, which have been absolutely pummeled over the last four years.Technically, shares are trading slightly above multiple inside candlesticks following a double bottom pattern of about one and a half years. With the formation finding support off the 50% retracement level and a supportive-looking stochastics set-up signaling better months and years ahead, GILD stock looks good to buy right now. * 10 'Buy-and-Hold' Stocks to Own Forever The TradeBuy GILD stock at current levels with an initial stop-loss below $59. On the upside, $85 - $90 looks like a good area for profit-taking while allowing this down-and-out value stock some room to run. Biogen (BIIB) Click to EnlargeMuch like GILD stock, shares of sector heavyweight Biogen (NASDAQ:BIIB) have been under extreme technical duress the past few years.Most recently, the pain in BIIB stock came after the company's announcement that it was axing a drug to treat Alzheimer's following poor results. The suffering came despite the fact that BIIB posted stronger-than-forecast results in late April.On the price chart, this biotech stock's technical beating since 2015 has resulted in a possible four-year long double-bottom pattern that's finding support in-between the 50% and 62% retracement levels. Coupled with an oversold stochastics that is a hair's breadth away from signaling a bullish crossover, confirmation of the pivot low looks imminent.The TradeBuy BIIB stock above May's candle high of $238.17 to confirm the pattern bottom. I'd suggest an initial stop beneath $214 and to take partial profits in-between $300 - $310.Disclosure: Investment accounts under Christopher Tyler's management currently do not own positions in any of the securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 3 Large-Cap Biotech Stocks to Buy for Massive Gains appeared first on InvestorPlace.

  • ETF Trends

    Biotech ETFs Could Use Some Mergers & Acquisitions

    The VanEck Vectors Biotech ETF (BBH) is up nearly 8% year-to-date, but some industry observers are speculating that for large-cap biotechnology stocks to rally again, some more mergers and acquisitions activity will be required. BBH holds 25 stocks and tracks the MVIS US Listed Biotech 25 Index, “which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment,” according to VanEck. Some well-known biotechnology companies are trailing the broader market this year as the healthcare sector itself is disappointing investors.

  • Biotech ETFs in Focus on String of Q1 Earnings Beats
    Zacks

    Biotech ETFs in Focus on String of Q1 Earnings Beats

    Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

  • Will Biotech ETFs Continue to Rally in Q1 Earnings?
    Zacks

    Will Biotech ETFs Continue to Rally in Q1 Earnings?

    Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .

  • Health Day Checkup of Medical ETFs: 5 Top Picks
    Zacks

    Health Day Checkup of Medical ETFs: 5 Top Picks

    M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

  • Top-Ranked ETF Winners in Dow's Longest Rally in 24 Years
    Zacks

    Top-Ranked ETF Winners in Dow's Longest Rally in 24 Years

    While there are winners in many corners of the space, some ETFs have crushed the Dow Jones by wide margins in three months.

  • Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
    Zacks

    Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

    Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

  • What's Behind the Biotech ETF Rally to Start 2019?
    Zacks

    What's Behind the Biotech ETF Rally to Start 2019?

    Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

  • Biotech ETFS: How To Pick Biotech Stock Winners And Avoid Volatility In 2019
    Investor's Business Daily

    Biotech ETFS: How To Pick Biotech Stock Winners And Avoid Volatility In 2019

    Biotech ETFs allow investors to buy into a basket of biotech stocks, rather than trying to select specific winners. The best biotech ETFs are diverse, with less volatility.

  • Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
    Zacks

    Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

    The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.

  • Business Wire

    VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs

    VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.

  • Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
    Market Realist

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion, compared to estimates for EPS of $4.03 on revenues of $3.88 billion during the third quarter of 2018.

  • Recommendations for Shire as of October 30
    Market Realist

    Recommendations for Shire as of October 30

    There are 11 analysts tracking Shire stock as of October 30. Four of them are recommending a “strong buy,” five are recommending a “buy,” and two are recommending a “hold.” None of them have recommended a “sell.” The changes in analysts’ estimates and recommendations are based on changing trends in the stock and the company’s performance.

  • What Analysts Recommend for Incyte ahead of Q3 Earnings
    Market Realist

    What Analysts Recommend for Incyte ahead of Q3 Earnings

    Wall Street analysts estimate Incyte’s (INCY) revenues will increase by ~17.7% to $449.2 million during the third quarter of 2018 compared to revenues of $381.5 million during the third quarter of 2017. Also, the earnings per share are estimated to be $0.40 for the third quarter of 2018 as compared to earnings per share of $0.08 for the third quarter of 2017. Incyte stock has fallen nearly 46.6% over the last 12 months and decreased by ~35.7% in 2018 year-to-date.

  • Amgen: Expect Nearly Flat Revenues in Q3
    Market Realist

    Amgen: Expect Nearly Flat Revenues in Q3

    As we discussed earlier, analysts expect Amgen (AMGN) to report nearly flat revenues at $5.77 billion during the third quarter. Amgen’s product portfolio includes human therapeutics.

  • Allergan’s Q3 2018 Estimates: Revenue Decline Expected
    Market Realist

    Allergan’s Q3 2018 Estimates: Revenue Decline Expected

    Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decrease 3.8% to $3.88 billion. Allergan has classified its business operations into three business segments: US Specialized Therapeutics US General Medicine International

  • Biogen: Analysts’ Recommendations on October 19
    Market Realist

    Biogen: Analysts’ Recommendations on October 19

    Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.

  • Business Wire

    VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry

    ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved in eSports events, and more

  • Analysts Are Mostly Positive on Neurocrine Biosciences
    Market Realist

    Analysts Are Mostly Positive on Neurocrine Biosciences

    Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.

  • Allergan’s Stock Performance and Estimates for Q3 2018
    Market Realist

    Allergan’s Stock Performance and Estimates for Q3 2018

    Allergan’s (AGN) product portfolio includes generic pharmaceutical products and specialty pharmaceutical products. The company’s business comprises three segments—US General Medicines, US Specialized Therapeutics, and International. The chart below compares Allergan’s revenues and EPS since the first quarter of 2017, as well as its estimates for the third quarter.

  • Ionis Pharmaceuticals’ Valuations on September 28
    Market Realist

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.